We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and SLS009 (tambiciclib), a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$32M
▲ +13.0% YoY
Op. Margin
–
ROIC
-30.51%
▲ +383.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$28M
▲ +19.8% YoY
Op. Cash Flow (TTM)
-$28M
▲ +19.8% YoY
Net Debt
-$138M
Net Cash Position
Cash & Equiv.
$138M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with SLS
Held by ETFs
SLS is in 33 US ETFs. The largest of them, with SLS's weight in each:
Sellas Life Sciences Group (SLS) in three numbers
Questions about Sellas Life Sciences Group
Is Sellas Life Sciences Group a high-quality business?
Sellas Life Sciences Group scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$138M, and its weakest is return on capital at -30.5%. The Quality tab shows every check against its target.
Does Sellas Life Sciences Group (SLS) pay a dividend?
No. Sellas Life Sciences Group (SLS) does not currently pay a dividend. The last payment in our data was in 2018, and nothing has been paid since. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 10 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 30 Oct 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in SLS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SLS
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.